PMID- 15602749
OWN - NLM
STAT- MEDLINE
DCOM- 20050511
LR  - 20131121
IS  - 0887-4476 (Print)
IS  - 0887-4476 (Linking)
VI  - 55
IP  - 3
DP  - 2005 Mar 1
TI  - 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat 
      rotational behavior and catalepsy.
PG  - 148-55
AB  - We have shown recently that 3,4-methylenedioxymethamphetamine (MDMA) has 
      symptomatic antiparkinsonian activity in rodent models of Parkinson's disease. In 
      search of its mechanism of action, we further investigated the enantiomers of 
      MDMA in the rotational behavioral model and catalepsy test. Catalepsy testing was 
      done in drug-naive unlesioned animals. The parkinsonian symptoms rigor and 
      akinesia (i.e., catalepsy) were induced by intraperitoneal administration of 
      haloperidol 0.5 mg/kg and measured repeatedly as descent latency from a 
      horizontal bar and a vertical grid. MDMA and both its enantiomers were effective 
      in counteracting haloperidol-induced catalepsy, but if given as racemic, the 
      effects were more pronounced than with the enantiomers. For testing of rotational 
      behavior, male Sprague Dawley rats were lesioned unilaterally with 
      6-hydroxydopamine (6-OHDA) at the medial forebrain bundle. Administration of 
      S-MDMA (5 mg/kg) produced ipsilateral rotations. R-MDMA was far less effective in 
      inducing ipsilateral rotations in 6-OHDA unilaterally lesioned rats, but when 
      S-MDMA was given additionally rotations immediately increased. Regarding their 
      overall antiparkinsonian effects, the S-enantiomer of MDMA was more effective 
      than its R-congener. R-MDMA was able to increase the actions of S-MDMA.
FAU - Lebsanft, Heike B
AU  - Lebsanft HB
AD  - Neuropharmacology, Zoological Institute, Faculty of Biology, University of 
      Tuebingen, 72076 Tuebingen, Germany. heike.lebsanft@uni-tuebingen.de
FAU - Kohles, Timo
AU  - Kohles T
FAU - Kovar, Karl-Artur
AU  - Kovar KA
FAU - Schmidt, Werner J
AU  - Schmidt WJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Synapse
JT  - Synapse (New York, N.Y.)
JID - 8806914
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Antiparkinson Agents)
RN  - 8HW4YBZ748 (Oxidopamine)
RN  - J6292F8L3D (Haloperidol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/chemistry/*pharmacology/therapeutic use
MH  - Animals
MH  - Antiparkinson Agents/chemistry/*pharmacology/therapeutic use
MH  - Behavior, Animal/drug effects/physiology
MH  - Catalepsy/chemically induced/*drug therapy/physiopathology
MH  - Denervation
MH  - Disease Models, Animal
MH  - Gait Disorders, Neurologic/chemically induced/*drug therapy/physiopathology
MH  - Haloperidol
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/chemistry/*pharmacology/therapeutic use
MH  - Oxidopamine
MH  - Parkinsonian Disorders/*drug therapy/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rotation
MH  - Stereoisomerism
EDAT- 2004/12/17 09:00
MHDA- 2005/05/12 09:00
CRDT- 2004/12/17 09:00
PHST- 2004/12/17 09:00 [pubmed]
PHST- 2005/05/12 09:00 [medline]
PHST- 2004/12/17 09:00 [entrez]
AID - 10.1002/syn.20102 [doi]
PST - ppublish
SO  - Synapse. 2005 Mar 1;55(3):148-55. doi: 10.1002/syn.20102.